A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients — KINDLE

Non-small-cell Lung Cancer (NSCLC) Clinical Trial

Official title:
A Multi-country, Multi-centre, Observational, Retrospective Study to Reveal the Patient Characteristics, Disease Burden, Treatment Patterns and Patient Journey of Stage III Non-small-cell Lung Cancer Patients

Status Completed

Clinical Trial Summary

This large multinational, non-interventional study (NIS), will retrospectively collect data derived from established medical records over a period of up to approximately 6 years (2013 to 2018), building a platform to capture and consolidate information on treatment patterns, Overall Survival (OS) and treatment effectiveness outcomes in the real-world setting.

Clinical Trial Description

This is multi-centre, multicountry, longitudinal cohort of patients with primary stage III NSCLC (Non-small Cell Lung Cancer), identified through the review of established patient medical records. Patients diagnosed with primary stage III NSCLC between 01 January 2013 and 31 December 2017 will be targeted for study inclusion, allowing at least 9 months of follow-up for living patients recruited at last day of the enrolment window. It is estimated that a total of approx. 2000 patients from 15-20 countries (approax.)

Patients' demographic and clinical characteristics and treatment patterns will be described. Clinical outcomes such as Progression-Free Survival (PFS), Time to Progression (TTP), Objective Response Rate (ORR) and Disease Control Rate (DCR) will be described by Line of Therapy (LOT). Overall survival will be described, where available. Healthcare resource utilisation will be described, as available from medical records. ;

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Non-small-cell Lung Cancer (NSCLC)

Clinical Trial Details

NCT number	NCT03725475
Study type	Observational
Source	AstraZeneca
Contact
Status	Completed
Phase
Start date	November 26, 2018
Completion date	September 30, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01874678` - A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer	N/A
Recruiting	`NCT06357598` - Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer	Phase 4
Recruiting	`NCT02448992` - Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer	Phase 2/Phase 3
Completed	`NCT02113813` - A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations	Phase 1
Active, not recruiting	`NCT04338620` - Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC	Phase 2
Completed	`NCT06232967` - PPIO-006 Primary Tumor Resection for IVa NSCLC